Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (101-110 of 442) with videos related to

Pageof 45
Sort By:
Blood Advances|July 3, 2019
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBIArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Haematologica|March 4, 2017
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMTJonathan Canaani, Bipin N Savani, Myriam Labopin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationEduardo Rodríguez-Arbolí, Myriam Labopin, Johanna Tischer, et al.
Bone Marrow Transplantation|March 24, 2020
Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working PartyEolia Brissot, Myriam Labopin, Domenico Russo, et al.
American Journal of Hematology|November 9, 2017
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantationJonathan Canaani, Bipin N Savani, Myriam Labopin, et al.
Blood|October 18, 2002
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT)Loïc Fouillard, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|August 26, 2022
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trialFanny Rialland, Audrey Grain, Myriam Labopin, et al.
Journal of Hematology & Oncology|June 1, 2017
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMTNicole Santoro, Annalisa Ruggeri, Myriam Labopin, et al.
British Journal of Haematology|February 4, 2012
Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantationOlle Ringdén, Myriam Labopin, Norbert-Claude Gorin, et al.
Pageof 45

Showing results (101-110 of 442) with videos related to

Sort By:
Pageof 45
Blood Advances|July 3, 2019
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBIArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Haematologica|March 4, 2017
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMTJonathan Canaani, Bipin N Savani, Myriam Labopin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationEduardo Rodríguez-Arbolí, Myriam Labopin, Johanna Tischer, et al.
Bone Marrow Transplantation|March 24, 2020
Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working PartyEolia Brissot, Myriam Labopin, Domenico Russo, et al.
American Journal of Hematology|November 9, 2017
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantationJonathan Canaani, Bipin N Savani, Myriam Labopin, et al.
Blood|October 18, 2002
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT)Loïc Fouillard, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|August 26, 2022
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trialFanny Rialland, Audrey Grain, Myriam Labopin, et al.
Journal of Hematology & Oncology|June 1, 2017
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMTNicole Santoro, Annalisa Ruggeri, Myriam Labopin, et al.
British Journal of Haematology|February 4, 2012
Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantationOlle Ringdén, Myriam Labopin, Norbert-Claude Gorin, et al.
Pageof 45